Beijing Bohui Innovation Biotechnology (SHE:300318) received regulatory approval from China's medical products administrator for a third class in vitro diagnostic reagent.
The nucleic acid detection kit targets rotavirus, norovirus, enteric adenovirus, astrovirus and sapovirus in stool samples, according to a May 31 filing with the Shenzhen bourse.
The certificate is valid until May 28, 2030.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.